tirzepatide 2024 SUMMIT: Improves Outcomes and Quality of Life For Patients With HFpEF and Obesity Compound Tirzepatide
Description
However, once the shortage resolved, the FDA mandated that compounding pharmacies stop producing tirzepatide
In clinical trials, tirzepatide was shown to be effective in helping overweight adults with at least one associated health problem lose weight
The mean body mass index was 32.6, and the mean duration of diabetes was 14.7 years
Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for chronic weight management) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
On the other hand the GLP1R in both cardiomyocytes and sinoatrial node cells can activate cyclic AMP (cAMP)-dependent signaling pathways
In the SURMOUNT-1 clinical trial, gastrointestinal adverse events were the most commonly reported side effects across all dose groups
